Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orexigen Thinks Contrave On The Verge Of Approval, Again

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech once again faces an FDA approval decision for its bupropion/naltrexone obesity combo, after a long and costly cardiovascular outcomes trial has kept the drug off the market.

You may also be interested in...

Why Orexigen’s Contrave May Win In The End

The biotech finally gleaned an FDA approval for its obesity pill Contrave and now faces the hurdle of commercialization, but plans to profit by the lessons from its competitors’ missteps.

The Skinny On Labeling For Orexigen’s Contrave

The biotech finally gains approval for its obesity agent and receives a label from FDA that, despite multiple contraindications and a boxed warning, is being looked upon favorably.

Orexigen’s Big Plans On Hold As FDA Hashes Out Post-Marketing Requirements

Weight loss drug Contrave delayed by three months while sponsor and agency discuss how to handle data transparency for ongoing cardiovascular outcomes trial.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts